期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 23, 页码 -出版社
MDPI
DOI: 10.3390/ijms222312741
关键词
breast cancer; calcitriol; drug combination; efficacy
资金
- Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico [256994, A1-S-10749]
- Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT) [IN208520]
- Direccion General de Asuntos del Personal Academico (DGAPA)
- Universidad Nacional Autonoma de Mexico (UNAM)
Vitamin D3 deficiency may increase the risk of breast cancer development, and calcitriol has been shown to inhibit cancer cell proliferation through various mechanisms and enhance the efficacy of anticancer drugs, although a standardized treatment regimen for breast cancer patients has not been fully established.
Preclinical, clinical, and epidemiological studies indicate that vitamin D3 (VD) deficiency is a risk factor for the development of breast cancer. Underlying mechanisms include the ability of calcitriol to induce cell differentiation, inhibit oncogenes expression, and modify different signaling pathways involved in the control of cell proliferation. In addition, calcitriol combined with different kinds of antineoplastic drugs has been demonstrated to enhance their beneficial effects in an additive or synergistic fashion. However, a recognized adjuvant regimen based on calcitriol for treating patients with breast cancer has not yet been fully established. Accordingly, in the present work, we review and discuss the preclinical and clinical studies about the combination of calcitriol with different oncological drugs, aiming to emphasize its main therapeutic benefits and opportunities for the treatment of this pathology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据